Increasing constitutional challenges to FTC adjudication could hasten Supreme Court review

Following Amgen and Horizon Therapeutics’ recent counterclaim against the Federal Trade Commission alleging that the agency’s in-house court violates the Constitution, a blueprint has emerged for dealmakers to challenge the constitutionality...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at